HOME
Hepatitis B
Hepatitis C
HIV and AIDS
HIV-HCV Coinfection
HIV-HBV Coinfection
Hepatitis C Main Section
FDA-approved Treatments
 Experimental Treatments
 HCV Articles by Topic

FDA-Approved Combination Therapy


Pegasys + Copegus (peginterferon alfa-2a + ribavirin)

PegIntron + Rebetol (peginterferon alfa-2b + ribavirin)

Roferon A + Ribavirin (Standard interferon alfa-2a + ribavirin)

Intron A + Rebetol (Standard Interferon alfa-2b + ribavirin)

Pegasys + Copegus
peginterferon alfa-2a + Copegus (ribavirin)

PEGASYS Medication Guide
Pegasys Product Information
Copegus Medication Guide
Copegus Product Information

Articles on Pegasys + Copegus
•
Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin - 8/19/2008
•Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin - 8/12/2008
•Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) - 8/05/2008
•Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study - 7/22/08
•Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials - 7/18/08
•12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients - 7/11/08
•Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3 - 7/08/08
•European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load - 7/04/08
•Pegylated Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial - 6/03/08
•Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3) - 5/20/08
•
Rapid Virologic Response to Peginterferon alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virologic Response and Relapse - 5/20/08
•
Amino Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated Interferon/ribavirin in Genotype 1b Patients - 5/20/08
•
Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection - 5/09/08
•
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin - 5/06/08
•
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin - 5/06/08
•
Cyclophilin Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon - 5/06/08
•
IDEAL Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate with PegIntron - 5/02/08
•
Milk Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders to Pegylated Interferon/Ribavirin - 5/02/08
•
R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded - 4/29/08
•
Large HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C) - 4/29/08
•
Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension - 4/29/08
•
HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance - 4/29/08
•
Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV - 4/29/08
•
Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate - 3/18/08
•
Pegylated Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis - 3/11/08
•
Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08
•
Hepatology Expert Discusses PegIntron vs Pegasys IDEAL Study Findings - 1/18/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08
•

How Ideal Is the IDEAL Trial?

PegIntron + Rebetol
peginterferon alfa-2b + Rebetol (ribavirin)

PEG-INTRON® Prescribing Information
 REBETOL® Prescribing Information

Articles on PegIntron + Rebetol
•Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin - 8/19/2008
•Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) - 8/05/2008
•Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study - 7/22/08
•Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials - 7/18/08
•12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients - 7/11/08
•European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load - 7/04/08
•Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years - 5/30/08
•Clearance of HCV at 5-Year Follow-up for Peginterferon alfa-2b ± Ribavirin Is Predicted by Sustained Virologic Response at 24 Weeks Post-Treatment - 5/20/08
•
Sustained Virologic Response and Relapse Rates With Peginterferon alfa-2b plus Ribavirin in Clinical Trials Are Comparable to Those in Community-Based Studies - 5/20/08
•
Rapid Virologic Response to Peginterferon alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virologic Response and Relapse - 5/20/08
•
Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3) - 5/20/08
•
Amino Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated Interferon/ribavirin in Genotype 1b Patients - 5/20/08
•
Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection - 5/09/08
•
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin - 5/06/08
•
Cyclophilin Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon - 5/06/08
•
IDEAL Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate with PegIntron - 5/02/08
•
Milk Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders to Pegylated Interferon/Ribavirin - 5/02/08
•
R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded - 4/29/08
•
Large HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C) - 4/29/08
•
Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension - 4/29/08
•
HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance - 4/29/08
•
Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV - 4/29/08
•
FDA Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin - 3/28/08
•
Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate - 3/18/08
•
Pegylated Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis - 3/11/08
•
FDA Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin - 3/28/08
•
Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08
•
Hepatology Expert Discusses PegIntron vs Pegasys IDEAL Study Findings - 1/18/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08
•
How Ideal Is the IDEAL Trial?

Intron A + Rebetol
(interferon alfa-2b + ribavirin)

Articles on Intron A + Rebetol
•Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes - 6/24/08
•Selected Hepatitis C Patients with Decompensated Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver Transplantation - 6/10/08
•Very Early Response to Interferon-based Therapy for Hepatitis C Is Apparent within the First 24 Hours - 5/30/08
•Response to Controlled-release Interferon Alfa-2b (Locteron) in Genotype 1 Hepatitis C Patients - 5/23/08
•Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C - 5/20/08
•
Clearance of HCV in Children at 5-Year Follow-up Is Predicted by Sustained Virologic Response at 24 Weeks Post Treatment With Interferon alfa-2b Plus Ribavirin - 5/20/08
•
Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C - 5/20/08
•
Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR) - 5/20/08
•
Response to Interferon-based Therapy in Hispanic Patients with Chronic Hepatitis C - 5/20/08
•
Rapid Virological Response Is a Stronger Predictor than HCV Genotype of Sustained Response to Interferon-based Therapy - 5/13/08
•
HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08
•
Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08

Roferon A + Ribavirin
(interferon alfa-2a + ribavirin)

Articles on Intron A + Rebetol
•Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes - 6/24/08
•Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C - 5/20/08
•
Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C - 5/20/08
•
Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR)- 5/20/08
•
HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08
•
Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07